Mackay Shields LLC Chemo Centryx, Inc. Transaction History

Mackay Shields LLC

$581 Million
Q3 2024

Shares

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2021 Aug 13, 2021	SELL	$9.59 - $50.88 $189,882 - $1.01 Million	-19,800 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$49.53 - $68.4 $653,796 - $902,880	-13,200 Reduced 40.0%	19,800 $1.01 Million
Q4 2020 Feb 16, 2021	BUY	$47.25 - $65.16 $80,325 - $110,772	1,700 Added 5.43%	33,000 $2.04 Million
Q3 2020 Nov 04, 2020	SELL	$46.35 - $61.69 $208,575 - $277,605	-4,500 Reduced 12.57%	31,300 $1.72 Million
Q2 2020 Jul 31, 2020	BUY	$38.58 - $65.07 $254,628 - $429,461	6,600 Added 22.6%	35,800 $2.06 Million
Q1 2020 May 08, 2020	BUY	$32.73 - $50.78 $955,715 - $1.48 Million	29,200 New	29,200 $1.17 Million

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mackay Shields LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mackay Shields LLC with notifications on news.